#China #Chicago #Hengrui Pharma #oncology studies #ASCO 2026

Hengrui Pharma's Noteworthy Participation at ASCO 2026

The prestigious American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from May 29 to June 2, 2026, stood as a beacon for advancements in oncology research. Among the many participants, Hengrui Pharma made a significant impact by presenting over 90 studies that spanned multiple tumor types and treatment strategies. This year marks another milestone in Hengrui's commitment to oncology research, reinforcing its position as a pioneer in innovative drug development.

Summary of Presentations and Findings

Oral Presentations from Chinese Researchers

In 2026, the ASCO Annual Meeting featured 94 oral presentations from Chinese research projects, including 12 late-breaking abstracts, a testament to the growing recognition of China's contributions to cancer research. Hengrui Pharma’s involvement included 91 accepted studies with 11 highlighted oral presentations, showcasing its diverse portfolio of therapeutic modalities and its continued investment in innovative approaches to combat cancer.

Extensive Oncology Pipeline

For 16 consecutive years, Hengrui Pharma has consistently shared data from its oncology portfolio at ASCO. This year, the research program covered various key cancer areas, such as gastrointestinal, breast, lung, urological, and gynecological cancers, along with supportive care in oncology. Hengrui's commitment is reflected in its offerings of 11 approved medications and 10 pipeline candidates, including a promising Class 2 new drug, classified by the NMPA.

The company's endeavors are bolstered by more than 10 technology platforms, which span small molecules, antibody-drug conjugates (ADCs), and unique antibody formats. Collectively, these platforms enhance Hengrui's capability to develop a broad array of therapies targeting various tumor types.

Notable Data Presented

Breast Cancer Innovations

Professor Zhenzhen Liu led the HELEN-Trio 011 study focused on triple-negative breast cancer, revealing that combining camrelizumab with chemotherapy yielded a pathological complete response rate (pCR) of 57.5%, outperforming the 45.4% pCR achieved using chemotherapy alone. Furthermore, the HELEN HER-013 study introduced a chemotherapy-de-escalated regimen of nab-PHPy, which demonstrated its noninferiority to standard treatment, representing a new hope for patients with HER2-positive early breast cancer who suffer from significant toxicity.

Progress in Gastrointestinal Cancers

The HORIZON-CRC01 study in colorectal cancer conducted by Professors Jin Li and Ying Yuan reported promising results with trastuzumab rezetecan, achieving a median progression-free survival of 5.5 months in patients with HER2-positive advanced colorectal cancer, signifying a significant improvement over conventional chemotherapy. Additionally, the multifaceted CARES-336 study explored an innovative regimen that combined camrelizumab with apatinib and transarterial chemoembolization (TACE), exhibiting promising gains in treatment efficacy for patients with unresectable hepatocellular carcinoma.

Breakthroughs in Urological Cancers

The FUZUPRO study illustrated the effectiveness of fluzoparib combined with standard therapy in metastatic castration-resistant prostate cancer, yielding a median radiographic progression-free survival of 24.8 months. Similarly, the combination treatment for muscle-invasive bladder cancer secured promising results, suggesting that the integration of these approaches could enhance outcomes significantly.

Supportive Cancer Care Advances

The Phase III PROTECT study provided new evidence of Hengrui's innovative antiemetic, demonstrating robust performance against standard regimens in managing chemotherapy-induced nausea and vomiting. This finding underscores the critical importance of supportive treatments in improving patient outcomes.

Looking Ahead

Hengrui Pharma is not only advancing 60 oncology candidates across various therapeutic areas, but it is also conducting over 150 clinical trials worldwide. The robust presentations at ASCO 2026 clarify Hengrui’s path forward, showcasing its relentless dedication to employing scientific advances towards tangible clinical benefits for cancer patients. As oncology research evolves, Hengrui remains steadfast in its pursuit of translating research discoveries into effective therapies designed to improve patient lives.

In conclusion, Hengrui Pharma’s presentations at ASCO 2026 signify an exciting chapter in oncology, promising hope for patients worldwide navigating the challenges of cancer treatment.